The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5401-5407

  Zhang, Baogang ^a,b   Lu, Zhihua ^a   Hou, Yuchuan ^a   Hu, Jinghai ^a   Wang, Chunxi ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Bladder cancer; Growth inhibition; siRNA; STAT3; Survivin

Indexed keywords

RECOMBINANT DNA; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CARCINOMA; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; MICE, INBRED BALB C; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; URINARY BLADDER NEOPLASMS;

EID: 84904750908     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1704-8     Document Type: Article

References (19)

1. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374(9685):239-49.
2. Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C, et al. Guidelines on bladder cancer. Eur Urol. 2002;41(2):105-12. (Pubitemid 35428874)
3. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
4. Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol. 2009;27(24):3929-37.
5. Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, Imai K, et al. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor andmalignant characteristics in T24 bladder cancer cells. Oncogene. 2006;25(8):1195-204.
6. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8(1):61-70.
7. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009;35(7):553-62.
8. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer.World J Urol. 2008;26(1):59-65.
9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. (Pubitemid 34164012)
10. Devarajan E, Huang S. STAT3 as a central regulator of tumor metastases. Curr Mol Med. 2009;9(5):626-33.
11. Burgess DJ. Tumorigenesis: dangerous micromanagement. Nat Rev Cancer. 2010;10(10):664.
12. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000;19(56):6613-26. (Pubitemid 32197700)
13. Chen CL, Cen L, Kohout J, Hutzen B, Chan C, Hsieh FC, et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 2008;7:78.
14. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Müller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer. 2005;116(1):100-4. (Pubitemid 40827761)
15. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109(6):1106-13. (Pubitemid 46435389)
16. Fuessel S, Herrmann J, Ning S, Kotzsch M, Kraemer K, Schmidt U, et al. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett. 2006;232(2):243-54. (Pubitemid 43170974)
17. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006;12(1):11-9. (Pubitemid 43166170)
18. Scheper MA, Nikitakis NG, Sauk JJ. Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer. Int J Oral Maxillofac Surg. 2007;36(7):632-9. (Pubitemid 46995753)
19. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 2004;23(28):4921-9. (Pubitemid 38932164)